Telangana DCA Makes 277 Seizures Since January

Hyderabad: Telangana accounts for over 35% of India’s pharmaceutical production, with Hyderabad earning the moniker ‘Bulk Drug Capital of India’.

The State has seen substantial growth in the pharmaceutical sector over the past few years. This growth, however, has also brought challenges, including a rise in the production and sale of spurious, unauthorised and counterfeit drugs.

Between January and July 2024, the Telangana Drugs Control Administration (DCA) conducted 12,575 inspections; this led to 277 seizures for various violations, 1,963 instances of departmental action, and 51 convictions.

The seizures, included six cases of spurious drugs; 61 cases of overpricing; 98 cases under the Drug and Magic Remedies (Objectionable Advertisements) Act, 1954; 34 cases involving unlicensed medical shops and warehouses; 14 cases of medicines marketed as food products; three cases of unlicensed cosmetics manufacturing; and two cases of production and sale of banned drugs.

According to the DCA, the State has 702 drug manufacturing units, 53 approved drug testing labs, 273 blood centres and 43,023 medical shops.

Some of the major seizure incidents by the DCA include a search in March at Kodad in Suryapet, where a person was found operating an unlicensed medical shop, leading to a seizure of stock worth ₹12.3 lakh. In April, unauthorised drug manufacturing was uncovered at Ovoid Pharmachem in Jeedimetla, Medchal Malkajgiri, leading to seizure of stocks worth ₹23.9 lakh.

Additionally, the DCA targeted clinics run by quacks (unqualified medical practitioners), conducting 59 searches and seizing medicines worth ₹33.16 lakh over the seven-month period.

Related Posts

  • Pharma
  • January 2, 2025
  • 29 views
Kwality Pharma gains on securing RCGM approval for Erythropoietin

Kwality Pharmaceuticals rose 3.19% to Rs 895 after the company secured approval from the Review Committee on Genetic Manipulation (RCGM) to begin pre-clinical toxicity studies for the recombinant Erythropoietin product,…

  • Pharma
  • January 2, 2025
  • 245 views
Sun Pharma sells entire stake in Japanese arm to Zaza Industrial Holdings

Sun Pharmaceutical Industries has announced the 100 per cent sale of its step-down subsidiary, Sun Pharma Japan Technical Operations, to Zaza Industrial Holdings K.K., Japan. The decision marks a strategic…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Kwality Pharma gains on securing RCGM approval for Erythropoietin

Kwality Pharma gains on securing RCGM approval for Erythropoietin

Man held with drugs worth Rs 2.50 cr, planned for New Year supply in Bengaluru

Man held with drugs worth Rs 2.50 cr, planned for New Year supply in Bengaluru

Sun Pharma sells entire stake in Japanese arm to Zaza Industrial Holdings

Sun Pharma sells entire stake in Japanese arm to Zaza Industrial Holdings

Bliss GVS Pharma Reaches 52-Week High of Rs. 181.35 with 42.53% Annual Return

Bliss GVS Pharma Reaches 52-Week High of Rs. 181.35 with 42.53% Annual Return

New Pharma Rules In India Effective Today: Are MSMEs Ready? What Will Change For The Industry

New Pharma Rules In India Effective Today: Are MSMEs Ready? What Will Change For The Industry

Sun Pharma To Sell 100 Percent Stake In Japanese Arm

Sun Pharma To Sell 100 Percent Stake In Japanese Arm